Low Rate of Mother-to-Child Transmission of HIV-1 After Nevirapine Intervention in a Pilot Public Health Program in Yaoundé, Cameroon

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue 3, 2003, Pages 274-280

  Ayouba, Ahidjo ^a   Tene, Gilbert ^b   Cunin, Patrick ^a   Foupouapouognigni, Yacouba ^a   Menu, Elisabeth ^c,d   Kfutwah, Anfumbom ^a   Thonnon, Jocelyn ^a   Scarlatti, Gabriella ^e   Monny Lobé, Marcel ^b   Eteki, Nicole ^g   Kouanfack, Charles ^g   Tardy, Michèle ^g   Leke, Robert ^g   Nkam, Maurice ^b   Nlend, Anne E ^f   Barré Sinoussi, Françoise ^c   Martin, Paul M V ^a   Nerrienet, Eric ^a  

^a CENTRE PASTEUR DU CAMEROUN   (Cameroon)

^b Centre Mere et Enfant   (Cameroon)

^c INSTITUT PASTEUR   (France)

^d INSERM   (France)

^e SAN RAFFAELE HOSPITAL   (Italy)

^f MINISTRY OF PUBLIC HEALTH   (Cameroon)

^g Hopital Central de Yaounde   (Cameroon)

Author keywords

BDNA; Cameroon; HIV 1; Mother to child; Nevirapine; Perinatal transmission; Prevention

Indexed keywords

NEVIRAPINE;

ADULT; ARTICLE; CAMEROON; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; NEWBORN; PERINATAL INFECTION; PRIORITY JOURNAL; SINGLE DRUG DOSE; VIRUS LOAD; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; CAMEROON; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOENZYME TECHNIQUES; INFANT; NEVIRAPINE; PILOT PROJECTS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PROSPECTIVE STUDIES; RNA, VIRAL; STATISTICS, NONPARAMETRIC;

EID: 0242580983     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200311010-00003     Document Type: Article

References (22)

1. UNAIDS. Report on Global HIV/AIDS epidemic. Geneva: World Health Organization; 2002.
2. DuBard CA, Newton WP. Elective cesarean delivery to prevent vertical transmission of HIV. J Fam Pract. 1999;48:493-494.
3. Newell ML. Prevention of mother-to-child transmission of HIV: challenges for the current decade. Bull World Health Organ. 2001;79:1138-1144.
4. Brocklehurst P, Volmink J. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev 2002(2):CD003510
5. Lyall EG, Blott M, de Ruiter A, et al. Guidelines for the management of HIV infection in pregnant women and the prevention of mother-to-child transmission. HIVMed. 2001;2:314-334.
6. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795-802.
7. Marseille E, Kahn JG, Mmiro F, et al. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet. 1999;354:803-809.
8. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001;15:1951-1957.
9. Anonymous. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures-worldwide, 1997-2000. MMWR Morb Mortal Wkly Rep. 2001;49:1153-1156.
10. Anonymous. WHO and UNAIDS continue to support use of nevirapine for prevention of mother-to-child HIV transmission. J Adv Nurs. 2002;39:519.
11. Menu E, Mbopi-Kéou F, Lagaye S, et al. Selection of maternal human immunodeficiency virus type 1 variants in human placenta. European Network for In Utero Transmission of HIV-1. J Infect Dis. 1999;179:44-51.
12. WHO, UNICEF, UNAIDS, WHO, UNICEF, UNAIDS Statement on Current Status of WHO/UNAIDS/UNICEF Policy Guidelines. Geneva: WHO; 1999.
13. Savage DF, Lhotska L. Recommendations on feeding infants of HIV positive mothers. WHO, UNICEF, UNAIDS guidelines. Adv Exp Med Biol. 2000;478:225-230.
14. Lallemant M, Jourdain G, Le Coeur S, et al. A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1. Perinatal HIV Prevention Trial (Thailand) Investigators. N Engl J. Med. 2000;343:982-991.
15. Descamps D, Collin G, Letoumeur F, et al. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J Virol. 1997;71:8893-8898.
16. Mauclere P, Damond F, Apetrei C, et al. Synthetic peptide ELISAs for detection of and discrimination between group M and group O HIV type 1 infection. AIDS Res Hum Retroviruses. 1997;13:987-993.
17. Rouet F, Montcho C, Rouzioux C, et al. Early diagnosis of paediatric HIV-1 infection among African breast-fed children using a quantitative plasma HIV RNA assay. AIDS. 2001;15:1849-1856.
18. Elbeik T, Alvord WG, Trichavaroj R, et al. Comparative analysis of HIV-1 viral load assays on subtype quantification: Bayer Versant HIV-1 RNA 3.0 versus Roche Amplicor HIV-1 Monitor version 1.5. J Acquir Immune Defic Syndr. 2002;29:330-339.
19. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS. 1999;13:479-486.
20. Moodley D, Moodley J, Coovadia H, et al. A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1. J Infect Dis. 2003;187:725-735.
21. Eshleman SH, Jackson JB. Nevirapine resistance after single dose prophylaxis. AIDS Rev. 2002;4:59-63.
22. CIPLA. Triomune 30/40: the first NRTI-NNRTI triple drug combination antiretroviral [abstract 518]. 7th European Conference on Clinical Aspects and Treatment of HIV Infection, Lisbon, 1999.